UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
VIVS
VivoSim Labs, Inc.
There isn't enough reported data to score VIVS yet.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
VIVS Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Weak | |
| Unavailable |
VIVS's revenue is currently stable, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
VIVS PE Valuation
VIVS has no meaningful PE right now: it lost money over the past year.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
VIVS Forward outlook
There aren't enough analyst estimates for VIVS to show an outlook.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over VIVS on earnings quality, reporting a profit while its opponent remains loss making.
VIVS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.51 | -666% |
| Q2 2026 | -$4.46 | -$4.38 |
| Q1 2026 | -$5.35 | -$3.65 |
| Q4 2025 | $1.87 | +$11.95 |
| Q3 2025 | $0.62 | +$13.22 |
| Q2 2025 | -$0.08 | +$16.36 |
| Q1 2025 | -$1.70 | +$17.50 |
| Q4 2024 | -$10.08 | +$16.08 |
VIVS has swung to a loss: it lost $3.51 per share over the past year, after a profit the year before.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over VIVS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over VIVS on profitability, with a higher operating margin.
VIVS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $51K | +82% |
| Q2 2026 | $18K | -51% |
| Q1 2026 | $40K | -22% |
| Q4 2025 | $26K | +8.3% |
| Q3 2025 | $28K | -6.7% |
| Q2 2025 | $37K | -5.1% |
| Q1 2025 | $51K | +76% |
| Q4 2024 | $24K | +380% |
VIVS's revenue is recovering but still below its 2019 peak: $51,000 last quarter, up 82% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -6502% | +2909 points |
| Q2 2026 | -15328% | -7449 points |
| Q1 2026 | -7968% | -1783 points |
| Q4 2025 | -10577% | +3873 points |
| Q3 2025 | -9411% | -717 points |
| Q2 2025 | -7878% | +804 points |
| Q1 2025 | -6184% | +4492 points |
| Q4 2024 | -14450% | +59150 points |
VIVS's operating margin was −6502% last quarter, up 2909 points from the same quarter a year ago.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
VIVS has the stronger cash trend. Its trailing FCF is up 15% versus its history, compared with UNH at up 5.2%.
VIVS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$3.2M | +$704K |
| Q1 2026 | -$2.2M | -$203K |
| Q4 2025 | -$2.3M | -$470K |
| Q2 2025 | -$3.9M | -$957K |
| Q1 2025 | -$2M | +$636K |
| Q4 2024 | -$1.8M | +$1.7M |
| Q3 2024 | -$2.7M | +$521K |
| Q2 2024 | -$3M | +$2.3M |
VIVS has burned cash in almost every quarter: −$10M over the past year, against −$10M the year before.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over VIVS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
VIVS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +214% | +11.2M shares |
| 1 year | +557% | +13.9M shares |
| 3 years | +2165% | +15.7M shares |
| 5 years | +2777% | +15.9M shares |
| Available history | +2925% | +15.9M shares |
VIVS has 16M diluted shares, up 557% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2022 | — |
| Q4 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
VIVS Net Leverage
VIVS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
VIVS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 23.5 | Oversold |
| Stochastic | 3.0 | Oversold |
VIVS's weekly RSI is 23 (oversold) and its Stochastic is 3 (oversold).
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
VIVS PE vs Healthcare Sector
| Metric | VIVS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
VIVS has no meaningful PE right now: it lost money over the past year.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over VIVS on trend strength, trading above more of its moving averages.
VIVS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.17 | 18% below |
| 20 week MA | $0.33 | 58% below |
| 50 week MA | $1.18 | 88% below |
| 100 week MA | $1.95 | 93% below |
| 200 week MA | $8.06 | 98% below |
VIVS is in a downtrend: it's below all five of its weekly moving averages, and 98% below its 200-week average.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over VIVS on returns for 2026, with the stronger performance.
VIVS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $96.0 | $191.5 | +100% |
| 2021 | $191.5 | $48.2 | -75% |
| 2022 | $48.2 | $19.1 | -60% |
| 2023 | $19.1 | $13.3 | -30% |
| 2024 | $13.3 | $3.67 | -72% |
| 2025 | $3.67 | $2.01 | -45% |
| 2026 YTD | $2.01 | $0.14 | -93% |
VIVS has finished five years in a row lower, and it's down 93% so far in 2026.